Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$17.14
▲ $0.02 (+0.1%)
Market data updated: 09/20 01:59 AM
News analyzed: 09/20/2026
Market Cap
$2.20B
Day Range
$16.53 - $17.30
52-Week Range
$11.00 - $22.67
Beta
—
Next Earnings
—
Support
$12.49
Resistance
$22.67
GENB is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+35.5% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 7/11 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 50
Price is above the 50-day average
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 7.0% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
75
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
72
Risk
42
Sentiment
100
Fundamental
No data available
Institutional
89
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Generate Biomedicines, Inc.** has focused on its optimistic market outlook and technological leadership in AI-driven drug discovery. Notably, an analyst from HC Wainwright raised the company’s price target to **$30**, citing strong potential. Additionally, Generate’s **CTO emphasized that while Nvidia GPUs are critical for AI, they alone won’t dictate success in the field**, highlighting the company’s unique approach. The limited headlines suggest broader industry interest in AI biotech but do not detail specific clinical or financial developments for Generate.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Generate Biomedicines, Inc.. News trend score: 100. Reason: 13 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
31
🎯 Conviction (vs. Emotion)
50
Psychology
34
Fundamentals
—
Technical
72
Valuation
—
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+18%
Market Narrative
74
Fundamental Reality
50
Narrative Gap
+24
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests GENB is experiencing **peer-driven herding**, as its underperformance relative to peers (-2.6% vs. -1.7%) aligns with collective action. The narrative gap (65 vs. 50) hints at overestimation of positive fundamentals, while euphoria (28) reflects selective optimism despite neutral momentum. Anchoring (22.2% above support) may reinforce reluctance to sell, but the key question is whether this herding is a temporary correction or a shift in sector-wide sentiment. Low panic/selling scores (5) imply no imminent liquidation pressure, though volatility (1.24x ATR) remains elevated relative to baseline.
Updated: 09/08/2026, 04:06 PM
What could change this?
👥 What the crowd believes
"HC Wainwright & Co. analyst maintains Generate Biomedicines with a Buy and raises the price target from $25 to $30."
"Nvidia GPUs are essential—but they won’t be enough to determine the winners in AI-driven drug discovery."
"Generate Biomedicines has delivered a 27.6% gain year to date."
📈 9D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Thorstein Veblen — 80/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
Based on Thorstein Veblen's documented principles, the model estimates that the stock’s growth appears aligned with real value creation, reflected in his relatively high score of 80. In contrast, Livermore, Graham, Fisher, Lynch, Bagehot and Graham‑Enterprising each cite insufficient data, resulting in neutral 50‑point scores and no clear buy signal. Efficient‑Market proponents, Schwager, Mackay, and both of Howard Marks’ frameworks assign modest to low scores (43‑28) and emphasize mixed evidence, late‑cycle risk, or crowd‑delusion patterns. Finally, Morgan Housel's zero score highlights volatility that would likely shake patient holders out, reinforcing the most cautious viewpoint.
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 80
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 60
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 43
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 42
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 40
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 36
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 28
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 23
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 141 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (7 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 13 positive, 7 neutral, 0 negative out of the last 20 articles.
SeekingAlpha · 14.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 8.9.2026
Benzinga · 8.9.2026
Benzinga · 8.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Yahoo · 7.9.2026
Barrons.com · 7.9.2026
Yahoo · 28.8.2026
BioPharma Dive · 28.8.2026
Benzinga · 28.8.2026
Benzinga · 28.8.2026
Yahoo · 27.8.2026
Benzinga · 27.8.2026
Yahoo · 27.8.2026
GuruFocus.com · 27.8.2026
Yahoo · 26.8.2026
Simply Wall St. · 26.8.2026
Benzinga · 26.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Generate Biomedicines, Inc. (GENB) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for GENB specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
GENB's technical score is 72/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 50-day average; MACD histogram is positive — rising momentum; RSI 58.3 — healthy positive momentum.
Based on the real signals StockIQ computed: ATR: 7.0% of price; Price is below the SAR point — downtrend; CMF 20 days: -0.08.
StockIQ has no recorded dividend payment history for GENB.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 8 purchases and 1 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| ARNOLD FRANCES | Open Market Sale | 1.9.2026 | 1,000 | -1,000 | $16.00 |
| Nally Michael | Open Market Purchase | 4.3.2026 | 20,000 | +20,000 | $12.00 |
| Bancel Stephane | Conversion of Derivative Security | 2.3.2026 | 1,100,000 | -1,100,000 | — |
| Nally Michael | Conversion of Derivative Security | 2.3.2026 | 1,000,000 | -1,000,000 | — |
| Mendillo Jane L | Open Market Purchase | 2.3.2026 | 1,500 | +1,500 | $16.00 |
| Nally Michael | Conversion of Derivative Security | 2.3.2026 | 658,327 | +658,327 | — |
| Bancel Stephane | Conversion of Derivative Security | 2.3.2026 | 724,160 | +724,160 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 2,109,704 | -2,109,704 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 1,265,822 | -1,265,822 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 2,109,704 | -2,109,704 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 2,953,586 | -2,953,586 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 1,265,822 | -1,265,822 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 2,531,644 | -2,531,644 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 12,723,940 | +12,723,940 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 13,702,224 | +13,702,224 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 987,491 | +987,491 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 18,483,785 | -18,483,785 | — |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 1,500,000 | -1,500,000 | — |
| AFEYAN NOUBAR | Open Market Purchase | 2.3.2026 | 1,562,500 | +1,562,500 | $16.00 |
| AFEYAN NOUBAR | Open Market Purchase | 2.3.2026 | 1,562,500 | +1,562,500 | $16.00 |
| Silvers Jason | Open Market Purchase | 2.3.2026 | 500 | +500 | $16.00 |
| Silvers Jason | Open Market Purchase | 2.3.2026 | 1,000 | +1,000 | $16.00 |
| AFEYAN NOUBAR | Conversion of Derivative Security | 2.3.2026 | 2,777,752 | +2,777,752 | — |
| Silvers Jason | Open Market Purchase | 2.3.2026 | 500 | +500 | $16.00 |
| Grous Beth | Open Market Purchase | 2.3.2026 | 300 | +300 | $16.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
7,456,033 shares short as of 2026-08-31 · vs. 7,275,413 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
41.3% of trading volume this week was short selling, vs. 53.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology